Clinical Evidence Framework: What Research Actually Shows Evidence for glutathione supplementation in GLP-1 users is sparse
Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing
In: Castelo-Branco P, Jeronimo C (eds) Histone modifications in therapy, 1st edn
In addition to skin benefits, glutathione promotes detoxification, immunological function, and overall wellness
There is an urgent unmet need to develop novel therapeutic approaches to enhance the tumour response to neoCRT to offer improved treatment and survival rates for rectal cancer patients